Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
About this study
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.
- Condition
- Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma, Acute Lymphatic Leukemia, Chronic Lymphatic Leukemia, Melanoma Stage IV
- Tested
- MB-CART19.1, MB-CART20.1, MB-CART2019.1
- Sponsor
- Miltenyi Biomedicine GmbH
Who can join
- Age
- Not specified
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 3
- Study condition: Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma, Acute Lymphatic Leukemia, Chronic Lymphatic Leukemia, Melanoma Stage IV
- Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up.
- Patient has provided informed consent prior to enrollment.
Exclusion 1
- No exclusion criteria
Where
7 sites, 2 recruiting
Charité Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Münster
Münster, Germany
Universitätsklinikum Köln
Cologne, Germany
Uniklinikum Erlangen
Erlangen, Germany
Universitätsmedizin Göttingen
Göttingen, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
and 1 more site on ClinicalTrials.gov
Contact
-
Clinical Trial Manager
+4922048306820 clinicaltrials.gov@miltenyi.com
Potential match only. Final eligibility is determined by the study team.